Mercado de Tratamento de Distúrbios do Sono no Médio Oriente e África – Tendências da Indústria e Previsão para 2028

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado de Tratamento de Distúrbios do Sono no Médio Oriente e África – Tendências da Indústria e Previsão para 2028

  • Healthcare
  • Publish Reports
  • Feb 2021
  • MEA
  • 350 Páginas
  • Número de tabelas: 151
  • Número de figuras: 49

>Mercado de Tratamento de Perturbações do Sono no Médio Oriente e África, por Tipo (Insónia, Apneia do Sono, Síndrome das Pernas Inquietas (SPI), Narcolepsia e outros), Tratamento (Terapia Farmacológica, Terapêutica Mecânica, Dispositivos de Avanço Mandibular, Estimulador do Nervo Hipoglosso, Cirurgia e Outros) Via Administração (Oral, Parentérica e Outros), Tipo de Medicamento (de Marca e Genéricos), Tipo de População (Crianças e Adultos), Utilizador Final (Hospitais, Clínicas Especializadas, Assistência Domiciliária, Centro Cirúrgico Ambulatório e Outros), Canal de Distribuição (Concurso Directo, Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online e Outros), País (África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egipto, Kuwait, Israel, Resto do Médio Oriente e África) Tendências e Previsões da Indústria para 2028

Mercado de Tratamento de Distúrbios do Sono no Médio Oriente e África

Análise de mercado e insights: Mercado de tratamento de distúrbios do sono no Médio Oriente e em África

Espera-se que o mercado de tratamento de distúrbios do sono ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com o CAGR de 7,0% no período de previsão de 2021 a 2028 e prevê-se que atinja os 372,83 milhões de USD até 2028. O aumento da prevalência de distúrbios do sono, como a apneia do sono, a insónia e a narcolepsia em todo o mundo, está a impulsionar o mercado de tratamento de distúrbios do sono.

Os distúrbios do sono, como a apneia do sono, a narcolepsia ou a insónia, são distúrbios médicos nos quais o doente tem dificuldade na manutenção do sono ou no início do sono. Este distúrbio causa funções mentais, físicas, sociais e emocionais irregulares. Os distúrbios do sono são tratados através de diferentes opções de tratamento de acordo com os sintomas dos doentes. A maioria dos doentes com apneia do sono é tratada através de terapias mecânicas.

O aumento dos distúrbios do sono aumentará a procura de opções de tratamento para os distúrbios do sono. Assim, prevê-se que o aumento do stress mental devido à vida agitada e aos hábitos pouco saudáveis ​​impulsione o crescimento do mercado de tratamento de distúrbios do sono. A extensão dos efeitos secundários pode ser fatal, causando medo do consumo nos doentes, levando a uma diminuição das vendas e da procura. Assim, o efeito adverso dos medicamentos atua como um fator restritivo para o crescimento do mercado de tratamento das perturbações do sono. O crescente avanço tecnológico está a atuar como uma oportunidade para aumentar a procura do mercado de tratamento de distúrbios do sono. O elevado custo do tratamento dos distúrbios do sono atua como um desafio para o crescimento do mercado de tratamento dos distúrbios do sono.

O relatório de mercado de tratamento de distúrbios do sono fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos. Para compreender a análise e o cenário do mercado de tratamento de distúrbios do sono, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Mercado de Tratamento de Distúrbios do Sono no Médio Oriente e África

Âmbito do mercado de tratamento de distúrbios do sono e tamanho do mercado

O mercado de tratamento das perturbações do sono está categorizado em sete segmentos notáveis ​​que se baseiam no tipo, tratamento, via de administração, tipo de medicamento, tipo de população, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

  • Com base no tipo, o mercado de tratamento de distúrbios do sono está segmentado em insónia, apneia do sono, síndrome das pernas inquietas (SPI), narcolepsia e outros. Em 2021, espera-se que o segmento da insónia domine o mercado de tratamento de distúrbios do sono devido ao avanço tecnológico, a fim de desenvolver opções de tratamento inovadoras para o distúrbio específico.
  • Com base no tratamento, o mercado de tratamento de distúrbios do sono está segmentado em terapia farmacológica, terapia mecânica, dispositivos de avanço mandibular, estimulador do nervo hipoglosso, cirurgia e outros. Em 2021, prevê-se que o segmento da terapia farmacológica domine o mercado de tratamento de distúrbios do sono porque estão disponíveis inúmeras classes de medicamentos para o tratamento de distúrbios do sono de acordo com os sintomas dos doentes.
  • Com base na via de administração, o mercado de tratamento das perturbações do sono está segmentado em oral, parentérica e outras. Em 2021, prevê-se que o segmento oral domine o mercado de tratamento de distúrbios do sono devido ao aumento da disponibilidade de medicamentos orais para o tratamento de distúrbios do sono, como a narcolepsia, a síndrome das pernas inquietas (SPI) e a insónia, entre outros .
  • Com base no tipo de medicamento, o mercado de tratamento de distúrbios do sono está segmentado em genéricos e de marca. Em 2021, prevê-se que o segmento dos genéricos domine o mercado de tratamento de distúrbios do sono devido ao aumento da disponibilidade de medicamentos genéricos para o tratamento de distúrbios do sono, como a gabapentina , comprimidos de zolpidem ER e comprimidos de eszopiclona, CIV entre outros.
  • Com base no tipo populacional, o mercado de tratamento de distúrbios do sono está segmentado em crianças e adultos. Em 2021, prevê-se que o segmento de adultos domine o mercado de tratamento de distúrbios do sono devido ao aumento da população geriátrica em todo o mundo, exigindo opções de tratamento mais avançadas.
  • On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others. In 2021, hospitals segment is expected to dominate the sleep disorder treatment market due to the financial capabilities of hospitals to purchase expensive equipment used in surgery along with the presence of trained professionals to operate the mechanical devices and prescribed medications.
  • On the basis of distribution channel, the sleep disorder treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is expected to dominate the sleep disorder treatment market as most of the drugs are procured through direct tender services.

Middle East and Africa Sleep Disorder Treatment Market Country Level Analysis

Middle East and Africa sleep disorder treatment market is analysed and market size information is provided by the country, type, treatment, route of administration, drugs type, population type, end user and distribution channel as referenced above.

The countries covered in the Middle East and Africa sleep disorder treatment market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and rest of Middle East and Africa.

Saudi Arabia is dominating in the Middle East and Africa sleep disorder treatment market due to technological advancements in the country along with the presence of major players of sleep disorder treatment in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

New Product Launches by Manufacturers is Creating New Opportunities for Players in the Sleep Disorder Treatment Market

The sleep disorder treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with sleep disorder treatment market sales, impact of advancement in the sleep disorder treatment market and changes in regulatory scenarios with their support for the sleep disorder treatment market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Sleep Disorder Treatment Market Share Analysis

O panorama competitivo do mercado de tratamento de distúrbios do sono fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados fornecidos acima estão apenas relacionados com o foco da empresa relacionado com o mercado de tratamento de distúrbios do sono.

Os principais players abordados no relatório de mercado de tratamento de distúrbios do sono no Médio Oriente e em África são a Jazz Pharmaceuticals, Inc., Pfizer Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Taj Pharmaceuticals Limited, Mallinckrodt, Alembic Pharmaceuticals Limited, Dr . , Koninklijke Philips NV, ResMed entre outros players nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo, que também estão a acelerar o mercado de tratamento de distúrbios do sono.

Por exemplo,

  • Em setembro de 2020, a Jazz Pharmaceuticals, Inc. anunciou a colaboração com o conteúdo educativo sobre saúde do sono da American Heart Association, de forma a fortalecer a sua área terapêutica de saúde do sono. Esta nova colaboração feita pela empresa aumentou a sua credibilidade no mercado.

A colaboração, as joint ventures e outras estratégias do player de mercado estão a potenciar o mercado empresarial no mercado de tratamento de distúrbios do sono, o que também oferece o benefício para a organização melhorar a sua oferta de tratamento de distúrbios do sono.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS

6 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS

7.1.2 RISE IN THE GERIATRIC POPULATION

7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS

7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS

7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES

7.2 RESTRAINTS

7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS

7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS

7.2.3 EMERGENCE OF GENERICS

7.3 OPPORTUNITIES

7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS

7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS

7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE

7.4 CHALLENGES

7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER

7.4.2 STRINGENT REGULATORY LANDSCAPE

7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE

8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE

9.1 OVERVIEW

9.2 INSOMNIA

9.2.1 INSOMNIA

9.2.2 CHILD INSOMNIA

9.2.3 OTHERS

9.3 SLEEP APNEA

9.3.1 OBSTRUCTIVE SLEEP APNEA

9.3.2 CENTRAL SLEEP APNEA

9.3.3 SNORING

9.3.4 INFANT SLEEP APNEA

9.3.5 OTHERS

9.4 RESTLESS LEGS SYNDROME (RLS)

9.5 NARCOLEPSY

9.5.1 TYPE 1

9.5.2 TYPE 2

10 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 PHARMACOLOGICAL THERAPY

10.2.1 CANNABIDIOL

10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS)

10.2.3 BENZODIAZEPINES

10.2.4 NON-BENZODIAZEPINE

10.2.5 MELATONIN RECEPTOR STIMULATOR

10.2.6 STIMULANTS

10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)

10.2.8 TRICYCLIC ANTIDEPRESSANTS

10.2.9 SODIUM OXYBATE (XYREM)

10.2.10 OTHERS

10.3 MECHANICAL THERAPY

10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)

10.3.2 BI-LEVEL PAP

10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP

10.3.4 ADAPTIVE SERVO-VENTILATION (ASV)

10.4 MANDIBULAR ADVANCEMENT DEVICES

10.5 HYPOGLOSSAL NERVE STIMULATOR

10.6 SURGERY

10.6.1 SOMNOPLASTY

10.6.2 TONSILLECTOMY

10.6.3 NASAL SURGERY

10.6.4 OTHERS

10.7 OTHERS

11 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 PILLS

11.2.3 OTHERS

11.3 PARENTERAL

11.4 OTHERS

12 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE

12.1 OVERVIEW

12.2 GENERICS

12.3 BRANDED

12.3.1 XYREM

12.3.2 EFFEXOR XR

12.3.3 AMBIEN

12.3.4 PRISTIQ

12.3.5 ZENZEDI

12.3.6 VYVANSE

12.3.7 OTHERS

13 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE

13.1 OVERVIEW

13.2 ADULT

13.3 CHILDREN

14 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CLINICS

14.4 HOME HEALTHCARE

14.5 AMBULATORY SURGICAL CENTER

14.6 OTHERS

15 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 HOSPITAL PHARMACY

15.4 RETAIL PHARMACY

15.5 ONLINE PHARMACY

15.6 OTHERS

16 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY GEOGRAPHY

16.1 MIDDLE EAST AND AFRICA

16.1.1 SOUTH AFRICA

16.1.2 SOUTH ARABIA

16.1.3 UAE

16.1.4 EGYPT

16.1.5 KUWAIT

16.1.6 ISRAEL

16.1.7 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 JAZZ PHARMACEUTICALS, INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 PFIZER INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 ELI LILLY AND COMPANY

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 VIATRIS INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 RESMED

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENTS

19.6 MALLINCKRODT

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 KONINKLIJKE PHILIPS N.V.

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 ALEMBIC PHARMACEUTICALS LIMITED

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 AMNEAL PHARMACEUTICALS LLC

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENTS

19.1 APOTEX INC.

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 ARBOR PHARMACEUTICALS

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 BMC MEDICAL CO.

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 DEVILBISS HEALTHCARE LLC

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 DR. REDDY’S LABORATORIES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 HIKMA PHARMACEUTICALS PLC

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENTS

19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENTS

19.18 OVENTUS

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)

19.19.1 COMPANY SNAPSHOT

19.19.2 REVENUE ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 SOMNOMED

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENTS

19.21 TAJ PHARMACEUTICALS LIMITED

19.21.1 COMPANY SNAPSHOT

19.21.2 PRODUCT PORTFOLIO

19.21.3 RECENT DEVELOPMENT

19.22 TARO PHARMACEUTICAL INDUSTRIES LTD.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENT

19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.23.1 COMPANY SNAPSHOT

19.23.2 REVENUE ANALYSIS

19.23.3 PRODUCT PORTFOLIO

19.23.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT

TABLE 3 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 6 MIDDLE EAST AND AFRICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 7 MIDDLE EAST AND AFRICA SLEEP SPNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 8 MIDDLE EAST AND AFRICA RESTLESS LEGS SYNDROME (RLS) IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 9 MIDDLE EAST AND AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 10 MIDDLE EAST AND AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 11 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2018-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 13 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 14 MIDDLE EAST AND AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 15 MIDDLE EAST AND AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 16 MIDDLE EAST AND AFRICA MANDIBULAR ADVANCEMENT DEVICES IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 17 MIDDLE EAST AND AFRICA HYPOGLOSSAL NERVE STIMULATOR IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 18 MIDDLE EAST AND AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 19 MIDDLE EAST AND AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 20 MIDDLE EAST AND AFRICA OTHERS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 21 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 24 MIDDLE EAST AND AFRICA PARENTERAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 25 MIDDLE EAST AND AFRICA OTHERS PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 26 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA GENERICS PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 28 MIDDLE EAST AND AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 30 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2018-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA ADULT IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 32 MIDDLE EAST AND AFRICA CHILDREN IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 33 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2018-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA HOSPITALS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 35 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 36 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 37 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTER IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 38 MIDDLE EAST AND AFRICA OTHERS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 39 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA DIRECT TENDER IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 41 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 42 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 43 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 44 MIDDLE EAST AND AFRICA HOSPITALS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 45 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 61 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 71 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 72 SOUTH AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 73 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 74 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 75 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 91 UAE SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 UAE INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 UAE SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 94 UAE NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 95 UAE SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 96 UAE PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 97 UAE MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 98 UAE SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 99 UAE PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 100 UAE ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 101 UAE PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 102 UAE BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 103 UAE SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 104 UAE SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 105 UAE SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 106 EGYPT SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 EGYPT INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 108 EGYPT SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 109 EGYPT NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 110 EGYPT SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 111 EGYPT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 112 EGYPT MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 113 EGYPT SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 114 EGYPT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 115 EGYPT ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 116 EGYPT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 117 EGYPT BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 118 EGYPT SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 119 EGYPT SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 120 EGYPT SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 121 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 KUWAIT INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 123 KUWAIT SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 124 KUWAIT NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 125 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 126 KUWAIT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 127 KUWAIT MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 128 KUWAIT SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 129 KUWAIT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 130 KUWAIT ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 131 KUWAIT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 132 KUWAIT BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 133 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 134 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 135 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 136 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 137 ISRAEL INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 138 ISRAEL SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)

TABLE 139 ISRAEL NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)

TABLE 140 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 141 ISRAEL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 142 ISRAEL MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 143 ISRAEL SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)

TABLE 144 ISRAEL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 145 ISRAEL ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)

TABLE 146 ISRAEL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 147 ISRAEL BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)

TABLE 148 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)

TABLE 149 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)

TABLE 150 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)

TABLE 151 REST OF MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION)

 

Lista de Figura

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION

FIGURE 11 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET

FIGURE 14 PROPORTION OF AMERICAN TWEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)

FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)

FIGURE 16 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020

FIGURE 17 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 18 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 19 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020

FIGURE 21 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION)

FIGURE 22 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 23 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 25 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 26 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)

FIGURE 27 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020

FIGURE 29 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION)

FIGURE 30 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028)

FIGURE 31 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020

FIGURE 33 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)

FIGURE 34 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028)

FIGURE 35 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020

FIGURE 37 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 38 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028)

FIGURE 39 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 41 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 42 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 43 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 45 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 46 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 48 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028)

FIGURE 49 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Middle East and Africa Sleep Disorder Treatment Market size will be worth USD 372.83 million by 2028.
The Middle East and Africa Sleep Disorder Treatment Market growth rate will be 7.0% by 2028.
The increased prevalence of sleep disorders such as sleep apnea, insomnia, and narcolepsy is the growth driver of the Middle East and Africa Sleep Disorder Treatment Market.
The type, treatment, route of administration, drugs type, population type, end user and distribution channel are the factors on which the Middle East and Africa Sleep Disorder Treatment Market research is based.
The major companies in the Middle East and Africa Sleep Disorder Treatment Market are Jazz Pharmaceuticals, Inc., Pfizer Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Taj Pharmaceuticals Limited, Mallinckrodt, Alembic Pharmaceuticals Limited, Dr. Reddy’s Laboratories Ltd., Koninklijke Philips N.V., ResMed.